Danaher Drops 11% Despite Earnings Beat — Overreaction or Wall Street Red Flag?

Danaher just delivered a textbook "beat-and-drop" mystery—plunging over 10% in a single session despite beating Q2 estimates and raising its full-year profit guidance. So why did investors panic? Management quietly trimmed its core revenue growth ceiling down to 3–4%, fueling fears over customer project delays in bioprocessing. Yet, underlying bioprocessing orders actually surged in the mid-teens. In this episode of Implied, we break down whether Wall Street is dramatically overreacting to short-term timing noise or if this life sciences giant is facing a longer post-pandemic recovery cycle than expected.